Search

Your search keyword '"Goebel, FD"' showing total 302 results

Search Constraints

Start Over You searched for: Author "Goebel, FD" Remove constraint Author: "Goebel, FD"
302 results on '"Goebel, FD"'

Search Results

3. Klinische Variabilität des autosomal-dominanten Diabetes des Jugendalters (MODY)*

6. Optimaler Beginn der antiretroviralen Therapie bei HIV-positiven Patienten

7. Divertikulose des Duodenums

8. Endoscopic Ultrasound in the Diagnosis and Staging of Gastrointestinal Kaposi's Sarcoma

9. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

10. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

11. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

12. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

13. What?s New in HIV/AIDS

15. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study

20. Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy

21. AIDS-Erkrankung und Psychopathologie - Beobachtungen aus dem psychiatrischen Konsiliardienst in einer internistischen Klinik

22. Adaptation of Red Cell Enzymes and Intermediates in Metabolic Disorders

23. Avanti 3: A Randomized, Double-Blind Trial to Compare the Efficacy and Safety of Lamivudine plus Zidovudine versus Lamivudine plus Zidovudine plus Nelfinavir in HIV-1-Infected Antiretroviral-Naive Patients

24. AIDS, multicentric Castleman's disease, and plasmablastic leukemia: report of a long-term survival.

25. Mönckeberg's sclerosis after sympathetic denervation in diabetic and non-diabetic subjects

27. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

29. Verwendung der Muskelsaugbiopsienadel für bioptische Diagnostik

30. What's new in HIV/AIDS: can science solve the global AIDS problem?

32. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes

33. Macro CK2 accumulation in tenofovir-treated HIV patients is facilitated by CK oligomer stabilization but is not predictive for pathology.

34. Longitudinal changes in HIV-1-specific T-cell quality associated with viral load dynamic.

35. [Osteoporosis, vitamin D deficiency and renale failure].

36. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.

37. Impact of changes in antigen level on CD38/PD-1 co-expression on HIV-specific CD8 T cells in chronic, untreated HIV-1 infection.

38. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.

39. The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.

40. Therapeutic vaccination reduces HIV sequence variability.

41. Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy.

42. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.

43. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.

44. Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.

45. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.

46. Clinical news from the XVI International AIDS Conference: The attempt of a summing up.

47. Treatment interruption in HIV therapy: a SMART strategy?

48. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.

49. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.

50. Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.

Catalog

Books, media, physical & digital resources